1. Home
  2. ON vs GMAB Comparison

ON vs GMAB Comparison

Compare ON & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ON Semiconductor Corporation

ON

ON Semiconductor Corporation

HOLD

Current Price

$55.26

Market Cap

20.4B

Sector

Technology

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$31.78

Market Cap

17.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ON
GMAB
Founded
1992
1999
Country
United States
Denmark
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.4B
17.4B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
ON
GMAB
Price
$55.26
$31.78
Analyst Decision
Buy
Strong Buy
Analyst Count
24
6
Target Price
$59.04
$40.40
AVG Volume (30 Days)
8.8M
1.4M
Earning Date
11-03-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
132.41
EPS
0.75
25.10
Revenue
$6,187,800,000.00
$3,845,670,022.00
Revenue This Year
N/A
$24.85
Revenue Next Year
$6.14
$16.67
P/E Ratio
$72.51
$12.31
Revenue Growth
N/A
29.57
52 Week Low
$31.04
$17.24
52 Week High
$70.58
$33.65

Technical Indicators

Market Signals
Indicator
ON
GMAB
Relative Strength Index (RSI) 63.42 59.84
Support Level $49.13 $31.32
Resistance Level $57.52 $32.41
Average True Range (ATR) 2.27 0.64
MACD 1.03 0.11
Stochastic Oscillator 78.55 73.67

Price Performance

Historical Comparison
ON
GMAB

About ON ON Semiconductor Corporation

Onsemi is a supplier of power semiconductors and sensors focused on the automotive and industrial markets. Onsemi is the second-largest power chipmaker in the world and the largest supplier of image sensors to the automotive market. While the firm used to be highly vertically integrated, it now pursues a hybrid manufacturing strategy for flexible capacity. Onsemi is pivoting to focus on emerging applications like electric vehicles, autonomous vehicles, industrial automation, and renewable energy.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: